Autocrine Production of PDGF Stimulated by the Tenascin-C-Derived Peptide TNIIIA2 Induces Hyper-Proliferation in Glioblastoma Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
28 Jun 2019
Historique:
received: 18 05 2019
revised: 20 06 2019
accepted: 25 06 2019
entrez: 3 7 2019
pubmed: 3 7 2019
medline: 18 12 2019
Statut: epublish

Résumé

Expression level of tenascin-C is closely correlated to poor prognosis in glioblastoma patients, while the substantial role of tenascin-C responsible for aggressive progression in glioblastoma cells has not been clarified. We previously found that peptide TNIIIA2, which is derived from the tumor-associated tenascin-C variants, has the ability to promote cell adhesion by activating β1-integrins. Our recent study demonstrated that potentiated activation of integrin α5β1 by TNIIIA2 causes not only a dysregulated proliferation in a platelet-derived growth factor (PDGF)-dependent manner, but also disseminative migration in glioblastoma cells. Here, we show that TNIIIA2 enhances the proliferation in glioblastoma cells expressing PDGF-receptorβ, even without exogenous PDGF. Mechanistically, TNIIIA2 induced upregulated expression of PDGF, which in turn stimulated the expression of tenascin-C, a parental molecule of TNIIIA2. Moreover, in glioblastoma cells and rat brain-derived fibroblasts, tenascin-C upregulated matrix metalloproteinase-2, which has the potential to release TNIIIA2 from tenascin-C. Thus, it was shown that autocrine production of PDGF triggered by TNIIIA2 functions to continuously generate a functional amount of PDGF through a positive spiral loop, which might contribute to hyper-proliferation in glioblastoma cells. TNIIIA2 also enhanced

Identifiants

pubmed: 31261783
pii: ijms20133183
doi: 10.3390/ijms20133183
pmc: PMC6651645
pii:
doi:

Substances chimiques

Peptide Fragments 0
Platelet-Derived Growth Factor 0
Tenascin 0
Receptors, Platelet-Derived Growth Factor EC 2.7.10.1
Matrix Metalloproteinase 2 EC 3.4.24.24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Science and Technology Agency
ID : 23590090

Références

Int J Cancer. 1999 Aug 12;82(4):477-83
pubmed: 10404058
Am J Pathol. 2000 May;156(5):1489-98
pubmed: 10793060
Clin Cancer Res. 2000 Oct;6(10):3944-8
pubmed: 11051242
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Cancer Res. 2002 Jul 1;62(13):3729-35
pubmed: 12097282
Clin Cancer Res. 2002 Jul;8(7):2455-62
pubmed: 12114453
Cancer Res. 1992 Jun 1;52(11):3213-9
pubmed: 1317261
Eur J Biochem. 1992 Apr 15;205(2):545-9
pubmed: 1374029
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nat Rev Cancer. 2006 Oct;6(10):764-75
pubmed: 16990854
J Biol Chem. 2007 Nov 30;282(48):34929-37
pubmed: 17901052
Leukemia. 2008 Feb;22(2):353-60
pubmed: 17972943
Cancer Res. 2007 Nov 1;67(21):10241-51
pubmed: 17974965
PLoS One. 2009 Nov 13;4(11):e7752
pubmed: 19915670
Cell Mol Life Sci. 2011 Oct;68(19):3175-99
pubmed: 21818551
Ups J Med Sci. 2012 May;117(2):99-112
pubmed: 22509804
Cancer Res. 2012 Jul 15;72(14):3463-70
pubmed: 22593187
Cancer Biol Ther. 2013 Apr;14(4):287-94
pubmed: 23358475
Cancer Res. 2013 May 15;73(10):3145-54
pubmed: 23644530
Cell Tissue Res. 2013 Nov;354(2):409-30
pubmed: 23963648
J Cell Sci. 2013 Sep 1;126(Pt 17):3799-804
pubmed: 23970415
Cancer Res. 2014 Jan 1;74(1):3-7
pubmed: 24327727
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
J Biol Chem. 2014 Jun 20;289(25):17699-708
pubmed: 24808173
Cancer Cell. 2014 Aug 11;26(2):288-300
pubmed: 25117714
Cell Adh Migr. 2015;9(1-2):48-82
pubmed: 25482829
Cell Adh Migr. 2015;9(1-2):131-40
pubmed: 25695402
Front Pharmacol. 2015 Nov 24;6:279
pubmed: 26635609
PLoS One. 2016 Sep 13;11(9):e0162525
pubmed: 27622612
Exp Mol Pathol. 2017 Apr;102(2):262-267
pubmed: 28223108
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634
pubmed: 28652369
Mol Cancer Ther. 2019 Jun 12;:null
pubmed: 31189613
Thromb Res. 1982 Jul 1;27(1):1-14
pubmed: 6812233
J Biol Chem. 1995 Apr 14;270(15):8650-4
pubmed: 7536739
J Biol Chem. 1997 Mar 28;272(13):8133-6
pubmed: 9079625
Clin Cancer Res. 1995 Sep;1(9):1035-41
pubmed: 9816077

Auteurs

Motomichi Fujita (M)

Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

Tetsuya Yamamoto (T)

Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.

Takuya Iyoda (T)

Department of Pharmacy, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 1-1-1 Daigaku-Doori, Sanyo-Onoda, Yamaguchi 756-0884, Japan.

Tatsuya Fujisawa (T)

Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

Reo Nagai (R)

Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

Chikako Kudo (C)

Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

Manabu Sasada (M)

Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

Hiroaki Kodama (H)

Faculty of Science and Engineering, Saga University, 1 Honjo-machi, Saga-city, Saga 840-8502, Japan.

Fumio Fukai (F)

Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. fukai@rs.noda.tus.ac.jp.
Translational Research Center, Research Institutes for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. fukai@rs.noda.tus.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH